R&D | Cutting-edge science and innovative research

R&D

Supporting the ageing process, pharmaceutically

Longevity is not a consumer trend, but a pipeline strategy p...

Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge.

News

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.

News

Kidney biotech R1's $78m debut, and other biofinancings

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

News

Lilly's triple agonist retatrutide passes diabetes test

Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.

News

Generic semaglutide in India, and other weight-loss news

Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.

News

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is

News

FDA sets out its thinking on psychedelic drug trials

The FDA has published its first-ever guidance document on clinical trials with psychedelic drugs, an emerging treatment category for psychiatric and substance use disorder

R&D

Partner Content

7th IPF Summit

Now in its 7th year, this is the undisputed (and only!) meeting dedicated to harnessing emerging biological understanding, employing novel preclinical models to cement translational confide

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.

News

Kidney biotech R1's $78m debut, and other biofinancings

Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

Longevity is not a consumer trend, but a pipeline strategy p...

Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge.

R&D

pharmaphorum podcast Episode 250, Rob DiCicco, Transcelerate

Making AI work where it matters, with Rob DiCicco

Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.

R&D

Beyond GLP-1: Preclinical hurdles and solutions for next-gen...

The development experience with GLP-1 analogues offers critical insights for navigating ADME challenges in contemporary peptide programmes.

Deep Dive

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

Beyond obesity: How GLP-1s are changing the game for hundred...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

pharmaphorum podcast Episode 249, Michelle Werner, Alltrna

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

R&D

pharmaphorum podcast Episode 248, Andrew Mackinnon, Medable

AI in clinical development & ‘white space’, with Andrew Mack...

Andrew Mackinnon, senior vice president and executive general manager at Medable, discusses leveraging AI to transform & accelerate development.

R&D

JPM2026 wrap-up with Nicole Raleigh and Jonah Comstock

On JPM2026 and healthcare investment today, with Jonah Comst...

Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.

Video

R&D

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.

R&D

The long-delayed promise of the microbiome, with Sam Possemi...

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

R&D

Allogeneic cell therapy isn’t dead, with Brian Culley

Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.

White Papers

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D